Moreover, the knockdown of PFKFB4 in two SCLC cell lines significantly reduced the IC50 of paclitaxel, demonstrating that PFKFB4 knockdown markedly enhances the sensitivity of SCLC to paclitaxel. Here, PFKFB4 is linked to small cell lung carcinoma.